Showing 20 of 32 recruiting trials for “chronic-beryllium-disease”
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
👨⚕️ Paul Szabolcs, MD, UPMC Children's Hospital of Pittsburgh📍 1 site📅 Started Mar 2026View details ↗
RecruitingNCT07127926 ↗
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
👨⚕️ Elizabeth M Kang, M.D., National Institute of Allergy and Infectious Diseases (NIAID)📍 1 site📅 Started Sep 2025View details ↗
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
👨⚕️ Stephanie J. Lee, MD, MPH, Fred Hutch/University of Washington Cancer Consortium📍 3 sites📅 Started Aug 2025View details ↗
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RecruitingNCT06605378 ↗
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)
👨⚕️ Elizabeth M Kang, M.D., National Institute of Allergy and Infectious Diseases (NIAID)📍 1 site📅 Started Jun 2024View details ↗
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →